Campaign

Company Summary :

Galenband is a unique heart rhythm monitoring platform which addresses an unmet clinical need around diagnosing intermittent heart rhythm problems.

Galenband addresses the problem of long-term cardiac monitoring by providing doctors with a convenient wearable diagnostic that far surpasses the limitations of adhesive-based solutions, which typically operate for periods of 10 days or less.

Atrial Fibrillation (AFib) is the most common heart rhythm abnormality. It burdens people with a 5X risk of stroke, and in those who have a stroke, 26% experience stroke recurrence due to undiagnosed AFib.

The short-term nature of adhesive-based solutions means that up to 80% of stroke patients do not receive adequate monitoring to identify and treat AFib to reduce their risk of stroke recurrence.

Key highlights:

• Technology: Wearable prototypes have been developed which successfully capture diagnostic quality ECG from the upper left arm with no need for wires, adhesives or patient interaction.

• Clinical Trials: A clinical trial has been carried out at the Beacon Hospital in Dublin. Galenband has been shown to perform excellently in comparison to hospital telemetry, achieving 97% sensitivity and 99.9% specificity in the detection of AFib. 

• Backed by Cardiologists and Industry Experts: Galenband is supported by world-renowned cardiologists, including leaders with track records from prestigious institutions such as Harvard, MIT, Abbott and St. Jude. 

• Awards: Galenband has received numerous awards recognising innovation, usability, and medical engineering excellence, including from the world’s top university – MIT, and taking first place in Enterprise Ireland Big Ideas, MedTech Startup Awards, and Seedcorn 

• Non-Dilutive Grant Funding: The Galenband project has been awarded a Disruptive Technologies Innovation Fund grant of €6.9M, which will complement private funds and support the journey to FDA clearance. 

• Experienced Leadership: The management team and board behind Galenband include seasoned entrepreneurs with prior exit experience and Forbes 30 Under 30 and MIT recognition.